News
Childhood Cancer Data Initiative’s (CCDI’s) Pediatric In Vivo Testing (PIVOT) Program Releases Molecular Characterization Data
Are you screening pediatric cancer therapies using patient-derived xenograft models? CCDI just released molecular characterization data that may help you in your research.
Accessing the Data
The NCI Cancer Research Data Commons’ General Commons stores the data. You can find it through the CCDI Hub Explore Dashboard under the following study accessions:
- phs003160: Sarcoma, Kidney, and Liver Cancers
- phs003161: Sarcomas and Other Solid Tumors
- phs003163: Neuroblastoma
- phs003164: Leukemia
Access to the data requires submitting a request through the database of Genotypes and Phenotypes (dbGaP) for each study accession of interest. Once you have access, you can analyze the data through the NCI-funded Seven Bridges’ Cancer Genomics Cloud (CGC), or you can download the data for analysis in your own analytical pipelines.
About the Data
The NCI-supported PIVOT program, an initiative of the Cancer Therapy Evaluation Program (CTEP), accelerates the discovery of more effective treatments for childhood cancers. Across four studies, researchers molecularly characterized more than 1,870 patient and patient-derived xenograft (PDX) tumor samples using methods such as whole exome, amplicon, and transcriptome sequencing, as well as methylation arrays. Novel therapeutic agents are screened against genomically characterized in-vivo models of pediatric solid tumors and leukemias, including PDX models.
By generating high-quality preclinical data, PIVOT supports a more reliable agent prioritization process, helping you identify therapies with the greatest potential for clinical success. Its strategy combines detailed tumor analysis with insights into drug exposure tolerances in both mice and humans, improving the predictive value of preclinical testing. By optimizing model selection and addressing challenges like low clinical trial enrollment and treatment resistance, PIVOT plays a critical role in advancing pediatric cancer drug development.
“By enabling access to molecularly characterized PDX models data from the PIVOT program, CCDI is empowering researchers to identify and prioritize promising therapies. This resource is essential for accelerating the pace of pediatric cancer drug development,” says Dr. Subhashini Jagu, supervisory health scientist administrator at NCI CBIIT.